Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
暂无分享,去创建一个
P. Scheltens | B. Dubois | B. Winblad | I. McKeith | M. Rossor | G. Waldemar | M. Emre | J. Georges | P. Tariska | I. Mckeith
[1] Bridget Kelly,et al. A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. , 1998, Archives of neurology.
[2] A. Mackinnon,et al. Combining cognitive testing and informant report to increase accuracy in screening for dementia. , 1998, The American journal of psychiatry.
[3] Lo J. Bour,et al. Slowing on Quantitative Spectral EEG Is a Marker for Rate of Subsequent Cognitive and Functional Decline in Early Alzheimer Disease , 1998, Alzheimer disease and associated disorders.
[4] C. Colosimo,et al. Donepezil in the treatment of progressive supranuclear palsy , 2001, Acta neurologica Scandinavica.
[5] B Miller,et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.
[6] S. Coons,et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. , 2005 .
[7] H. Nelson. A Modified Card Sorting Test Sensitive to Frontal Lobe Defects , 1976, Cortex.
[8] A Drzezga,et al. Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration , 2002, Neurology.
[9] S. Gauthier,et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.
[10] C. Ballard,et al. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease , 2006 .
[11] E. Tangalos,et al. CME Practice parameter: , 2022 .
[12] L. Schneider,et al. Estrogen levels do not correlate with improvement in cognition. , 2003, Archives of neurology.
[13] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[14] J. Cummings,et al. Alzheimer's disease and related disorders annual , 2000 .
[15] L. Schneider,et al. Memantine for dementia. , 2006, The Cochrane database of systematic reviews.
[16] J. Wiltfang,et al. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.
[17] J. Kornhuber,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[18] A. Nordberg,et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer’s disease , 2000, Neurobiology of Aging.
[19] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[20] Anthony Gamst,et al. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .
[21] M. De Hert,et al. Cost of disorders of the brain in Europe. , 2006, European journal of neurology.
[22] D. Gifford,et al. Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. , 2000, Archives of internal medicine.
[23] Turan M. Itil,et al. A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia , 1997 .
[24] Sasha Bozeat,et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.
[25] B. Steinhoff,et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. , 1996, Archives of neurology.
[26] G. Wilcock,et al. Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial , 2004, European journal of neurology.
[27] D. Sparks,et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. , 2005, Current Alzheimer Research.
[28] L. Bellak,et al. Geriatric psychiatry : a handbook for psychiatrists and primary care physicians , 1976 .
[29] H. Yamanouchi,et al. Access www.neurology.org now for full-text articles , 2001, Neurology.
[30] B. Boeve,et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy , 2001, Movement disorders : official journal of the Movement Disorder Society.
[31] Z Walker,et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.
[32] E. Perry,et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.
[33] C. Berr,et al. Cost of dementia in Europe , 2005, European journal of neurology.
[34] Frederik Barkhof,et al. Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia: An Interobserver Study , 2003, Stroke.
[35] K. Blennow,et al. CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.
[36] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[37] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[38] C. K. Y. Chan,et al. Screening for Dementia: A Preliminary Study on the Validity of the Chinese Version of the Blessed-Roth Dementia Scale , 2003 .
[39] A. Schatzberg,et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. , 1997, JAMA.
[40] R. Faber,et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.
[41] A. Crawley,et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[42] Ove Almkvist,et al. Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease , 1999 .
[43] J. Orgogozo,et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.
[44] Diederick E Grobbee,et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study , 1995, BMJ.
[45] P Julin,et al. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study , 2000, Journal of neurology, neurosurgery, and psychiatry.
[46] J. Martín,et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[47] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[48] N. Waugh,et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. , 2001, Health technology assessment.
[49] Paul Duberstein,et al. How effective are interventions with caregivers? An updated meta-analysis. , 2002, The Gerontologist.
[50] L. Flicker,et al. Piracetam for dementia or cognitive impairment. , 2004, The Cochrane database of systematic reviews.
[51] C. Jack,et al. MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.
[52] M. Albert,et al. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. , 1993, Archives of neurology.
[53] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[54] M. Brainin,et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.
[55] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[56] R. Doody,et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.
[57] H J Koch,et al. A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.
[58] M. Hallett,et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy , 2001, Neurology.
[59] K. Blennow,et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.
[60] K. Davis,et al. A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.
[61] K. Blennow,et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.
[62] Dirk Deleu,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.
[63] B. Oken. Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.
[64] Jean-Claude Baron,et al. Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.
[65] H. Wiśniewski,et al. In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.
[66] B. Seltzer,et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.
[67] D. Bereczki,et al. The Cochrane Database of Systematic Reviews , 2003 .
[68] Jan A Staessen,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.
[69] C Jonker,et al. The diagnostic value of electroencephalography in mild senile Alzheimer's disease , 1999, Clinical Neurophysiology.
[70] W. Herrmann,et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. , 1997, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[71] V. Hachinski,et al. Electroencephalography as an aid in the exclusion of Alzheimer's disease. , 1994, Archives of neurology.
[72] F Barkhof,et al. The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m‐HMPAO Single‐Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community‐Dwelling Elderly Population , 1997, Alzheimer disease and associated disorders.
[73] M. McDonagh,et al. A Systematic Review of the Efficacy and Safety of Atypical Antipsychotics in Patients with Psychological and Behavioral Symptoms of Dementia , 2006, Journal of the American Geriatrics Society.
[74] C. Schweiger. [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[75] J. Ridley. Studies of Interference in Serial Verbal Reactions , 2001 .
[76] K. Jellinger,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.
[77] Nick C Fox,et al. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia , 2001, Neurology.
[78] B. Sahakian,et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.
[79] G. Samsa,et al. Alzheimer disease: operating characteristics of PET--a meta-analysis. , 2004, Radiology.
[80] G. Frisoni,et al. Linear measures of atrophy in mild Alzheimer disease. , 1996, AJNR. American journal of neuroradiology.
[81] P. Macfarlane,et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.
[82] P. Harper,et al. Genetic testing for Huntington's disease. , 1990, BMJ.
[83] J. Cummings. Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[84] C. Hirsch. Alzheimer's Disease: A Physician's Guide to Practical Management , 2004 .
[85] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[86] L. Candelise,et al. Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.
[87] J. López-arrieta,et al. Nimodipine for primary degenerative, mixed and vascular dementia. , 2000, The Cochrane database of systematic reviews.
[88] U. Salvolini,et al. Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimer’s Disease , 1998, European Neurology.
[89] Šimon Scharf,et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.
[90] K. Blennow,et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.
[91] M. Ebell. Donepezil in the treatment of vascular dementia. , 2004, American family physician.
[92] Philip Scheltens,et al. Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry , 1999, Psychiatry Research: Neuroimaging.
[93] L. Flicker,et al. Selegiline for Alzheimer's disease. , 2003, The Cochrane database of systematic reviews.
[94] C. Mariani,et al. Observations on dementias with possibly reversible symptoms , 1999, Aging.
[95] J T O'Brien,et al. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment , 1997, Psychological Medicine.
[96] Jacob Cohen,et al. A comprehensive support program: effect on depression in spouse-caregivers of AD patients. , 1995, The Gerontologist.
[97] G. Wilcock,et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.
[98] A. Spector,et al. Aspirin for vascular dementia. , 2000, The Cochrane database of systematic reviews.
[99] G. Small,et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. , 2003, Clinical therapeutics.
[100] P. Tariot,et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.
[101] Barry Horwitz,et al. Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type , 1995, Psychiatry Research.
[102] P. Cras,et al. Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. , 1999, Journal of Alzheimer's disease : JAD.
[103] G C Roman,et al. Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.
[104] G. Foster,et al. THE USE OF CT SCANNING IN DEMENTIA , 1999, International Journal of Technology Assessment in Health Care.
[105] K. Laake,et al. Statins for the reduction of risk of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.
[106] P. Scheltens,et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.
[107] J. Hodges,et al. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. , 1992, Brain : a journal of neurology.
[108] A. Kaszniak,et al. Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.
[109] H. Wiśniewski,et al. Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer's Disease , 1997, International Psychogeriatrics.
[110] A. W. Lemstra,et al. Een klinisch algoritme voor het gebruik van de 14-3-3-liquortest bij de diagnostiek van de ziekte van Creutzfeldt-Jakob , 2001 .
[111] A. Boxer,et al. Clinical Features of Frontotemporal Dementia , 2005, Alzheimer disease and associated disorders.
[112] G. Livingston,et al. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis , 2000, International journal of geriatric psychiatry.
[113] I. McKeith,et al. Behavioural changes and psychological symptoms in dementia disorders , 2005, The Lancet Neurology.
[114] S. Ferris,et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. , 1993, The Gerontologist.
[115] T. McRae,et al. Comments on Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.
[116] G. Wilcock,et al. Clinical utility of computed tomography in the assessment of dementia: a memory clinic study , 2004, International journal of geriatric psychiatry.
[117] J. Hodges,et al. Transient epileptic amnesia: a description of the clinical and neuropsychological features in 10 cases and a review of the literature , 1998, Journal of neurology, neurosurgery, and psychiatry.
[118] A. Wallin,et al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia , 2000, Journal of the Neurological Sciences.
[119] A. Bava,et al. Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.
[120] B. Vellas,et al. Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.
[121] Anthony F Jorm. Methods of Screening for Dementia: A Meta‐Analysis of Studies Comparing an Informant Questionnaire with a Brief Cognitive Test , 1997, Alzheimer disease and associated disorders.
[122] L. Schneider,et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[123] James A. Mortimer,et al. Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .
[124] K Masaki,et al. Practice parameter: Risk of driving and Alzheimer’s disease , 2001, Neurology.
[125] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[126] A. Colchester,et al. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. , 2001, Clinical radiology.
[127] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[128] C. Marra,et al. Effects of aging and of Alzheimer's disease on verbal memory. , 1995, Journal of clinical and experimental neuropsychology.
[129] N. Qizilbash. Evidence based dementia practice , 2002 .
[130] B. Lebowitz,et al. Behavioral and Psychological Symptoms of Dementia: A Clinical and Research Update , 2000, International Psychogeriatrics.
[131] C. Cotman,et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.
[132] H C Liu,et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD , 2000, Neurology.
[133] N. Tabet,et al. Vitamin E for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.
[134] R. Petersen,et al. Frequency of tau mutations in three series of non‐Alzheimer's degenerative dementia , 1999, Annals of neurology.
[135] K. Davis,et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.
[136] W. Markesbery,et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.
[137] T. Erkinjuntti,et al. Usefulness of the Clinical Dementia Rating Scale in Screening for Dementia , 1995, International Psychogeriatrics.
[138] G Lundberg,et al. The Swedish National Road Administration , 1996 .
[139] M. Philpot,et al. Functional Imaging in Dementia , 1989 .
[140] T. Dening,et al. Antidepressants for treating depression in dementia. , 2002, The Cochrane database of systematic reviews.
[141] A. C. Stein,et al. Practice parameter: Risk of driving and Alzheimer’s disease (an evidence-based review) , 2000, Neurology.
[142] A. Stöffler,et al. New Approaches to Clinical Trials in Vascular Dementia: Memantine in Small Vessel Disease , 2002, Cerebrovascular Diseases.
[143] R. Görtelmeyer,et al. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. , 1992, Arzneimittel-Forschung.
[144] M. Fioravanti,et al. Nicergoline for dementia and other age associated forms of cognitive impairment , 2001 .
[145] K. Laake,et al. Statins for the prevention of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.
[146] P. Knipschild,et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. , 2003, Journal of clinical epidemiology.
[147] Arthur L. Benton,et al. Differential behavioral effects in frontal lobe disease , 1968 .
[148] Frederik Barkhof,et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.
[149] H. Budka,et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.
[150] I. Zerr,et al. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. , 2000, Archives of neurology.
[151] A. M. Clarfield,et al. The decreasing prevalence of reversible dementias: an updated meta-analysis. , 2003, Archives of internal medicine.
[152] P. Scheltens,et al. CSF tau and Aβ42 are not useful in the diagnosis of frontotemporal lobar degeneration , 2004, Neurology.
[153] Bruce L. Miller,et al. Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .
[154] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .
[155] C. Lines,et al. Rofecoxib , 2004, Neurology.
[156] J. Avorn,et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.
[157] Henry Brodaty,et al. Meta‐Analysis of Psychosocial Interventions for Caregivers of People with Dementia , 2003, Journal of the American Geriatrics Society.
[158] Jeffrey L. Cummings,et al. The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.
[159] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[160] J. Birks,et al. Donepezil for vascular cognitive impairment. , 2004, The Cochrane database of systematic reviews.
[161] B L Miller,et al. Estrogen for Alzheimer’s disease in women , 2000, Neurology.
[162] F. Baas,et al. [Clinical algorithm for cerebrospinal fluid test of 14-3-3 protein in diagnosis of Creutzfeldt-Jacob disease]. , 2001, Nederlands tijdschrift voor geneeskunde.
[163] K. Kosaka,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.
[164] J. Touchon,et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period , 2005, Current medical research and opinion.
[165] J. O'Brien,et al. Volumetric and visual assessment of the mesial temporal structures in Alzheimer's disease. , 1994, Australian and New Zealand journal of medicine.
[166] J. Vanneste,et al. Diagnosis and management of normal-pressure hydrocephalus , 2000, Journal of Neurology.
[167] I. McKeith. A Physician’s Guide to Practical Management , 2005 .
[168] G. McGwin,et al. Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.
[169] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[170] J. Cummings,et al. Comorbidity in dementia: an autopsy study. , 2004, Archives of pathology & laboratory medicine.
[171] M. Rossor,et al. EEG abnormalities in frontotemporal lobar degeneration , 2004, Neurology.
[172] M. Rossor,et al. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.
[173] Charles DeCarli,et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.
[174] J. Luxenberg,et al. Valproic acid for agitation in dementia. , 2002 .
[175] Nick C Fox,et al. Epilepsy presenting as AD: Neuroimaging, electroclinical features, and response to treatment , 2002, Neurology.
[176] Klaus P. Ebmeier,et al. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[177] R. Mohs,et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.
[178] Lon S Schneider,et al. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.
[179] M. Michalopoulou,et al. Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.
[180] I. Zalonis,et al. CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population , 2003, European journal of neurology.
[181] K. Yaffe,et al. Hormone replacement therapy to maintain cognitive function in women with dementia. , 2009, The Cochrane database of systematic reviews.
[182] K. Ishii,et al. Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. , 2000, Radiology.
[183] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[184] Kenneth Rockwood,et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.
[185] J. Luxenberg,et al. Haloperidol for agitation in dementia. , 2002, The Cochrane database of systematic reviews.
[186] J. Duchek,et al. Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. , 1997, Archives of neurology.
[187] Roberto Pastor-Barriuso,et al. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.
[188] T. Hope,et al. Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD) , 1996, British Journal of Psychiatry.
[189] Marina Boccardi,et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia , 2003, Neurobiology of Aging.
[190] S H Ferris,et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. , 1987, The Journal of clinical psychiatry.
[191] C. Callahan,et al. The Efficacy of Pentoxifylline in the Treatment of Vascular Dementia: A Systematic Review , 2003, Alzheimer disease and associated disorders.
[192] Kristine Yaffe,et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.
[193] J. Cummings,et al. Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease , 2004 .
[194] P. Scheltens,et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.
[195] J. Corey-Bloom,et al. Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[196] E. Perry,et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial , 2000, International journal of geriatric psychiatry.
[197] J. Birks,et al. Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.
[198] I. Bone,et al. Diagnostic strategies in CADASIL , 2003, Neurology.
[199] Hilkka Soininen,et al. Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.
[200] P. Lantos,et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies , 1999, British Journal of Psychiatry.
[201] Gwenn S. Smith,et al. EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.
[202] Rachelle Doody,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[203] Norman Sartorius,et al. Access to diagnostic evaluation and treatment for dementia in Europe , 2007, International journal of geriatric psychiatry.
[204] Shalini Jha,et al. The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
[205] Robert B Wallace,et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.
[206] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[207] L. Wilkins. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.
[208] J. Olesen,et al. The burden of brain diseases in Europe , 2003, European journal of neurology.
[209] J. Swartz,et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.
[210] H C Liu,et al. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening tool for dementia for a predominantly illiterate chinese population , 1995, Neurology.
[211] G. Waldemar,et al. Potentially reversible conditions in 1000 consecutive memory clinic patients , 2002, Journal of neurology, neurosurgery, and psychiatry.
[212] J. O’Brien,et al. Treating behavioural and psychological signs in Alzheimer's disease , 1999, BMJ.
[213] C. Ballard,et al. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. , 2002, The Cochrane database of systematic reviews.
[214] M. Verbeek,et al. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases , 2003, Annals of clinical biochemistry.
[215] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[216] M. Rossor,et al. Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine , 2005, Neurology.
[217] Y. Agid,et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .
[218] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[219] D. Richards,et al. A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia , 2001, Aging & mental health.
[220] H J Sagar,et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. , 1992, Brain : a journal of neurology.
[221] S. Salloway,et al. Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial , 2003, Stroke.
[222] Anthony F Jorm,et al. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms , 1989, Psychological Medicine.
[223] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[224] B. Winblad,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.
[225] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[226] J. Argente,et al. Insulin-like growth factor I, insulin-like growth factor binding proteins, and growth hormone binding protein in Spanish premature and full-term newborns. , 1996, Hormone research.
[227] K. Ditzler. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.
[228] B. Sahakian,et al. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia , 2001, Journal of neurology, neurosurgery, and psychiatry.
[229] F. Sherriff,et al. Memantine for dementia. , 2005, The Cochrane database of systematic reviews.
[230] R. S. Doody, MD, PhD,et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[231] Ann Marie Hake,et al. The use of memantine in dementia with Lewy bodies. , 2005, Journal of Alzheimer's disease : JAD.
[232] Serge Gauthier,et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.
[233] H Merskey,et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. , 1993, Archives of neurology.
[234] H. Feldman,et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.
[235] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[236] J. Cummings,et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.
[237] K. Johansson,et al. The 1994 International Consensus Conference on Dementia and Driving: A Brief Report , 1997, Alzheimer disease and associated disorders.
[238] H J Testa,et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia , 2002, Acta neurologica Scandinavica.
[239] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.
[240] K. Blennow,et al. Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations , 2001, Experimental Neurology.
[241] B. Winblad,et al. 3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy , 2006, Dementia and Geriatric Cognitive Disorders.
[242] D. Davies,et al. MYOCARDIAL DISORDERS IN THE ELDERLY. , 1963, Lancet.
[243] J. Wiltfang,et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.
[244] A D Roses,et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.
[245] P. Scheltens,et al. Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.
[246] Desmond O’Neill,et al. Health and Relicensing Policies for Older Drivers in the European Union , 2000, Gerontology.
[247] Dag Aarsland,et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.
[248] K. Blennow,et al. Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia , 2002, Dementia and Geriatric Cognitive Disorders.
[249] J. Birks,et al. Ginkgo biloba for cognitive impairment and dementia. , 2007, The Cochrane database of systematic reviews.
[250] J. Birks,et al. Ginkgo biloba for cognitive impairment and dementia (Review) , 2017 .
[251] B. Dubois,et al. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. , 2002, Presse medicale.
[252] W F Stewart,et al. Screening for dementia with the Memory Impairment Screen , 1999, Neurology.
[253] L. Schneider,et al. Galantamine for Alzheimer's disease and mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.
[254] R DeJong,et al. Measurement of quality-of-life changes in patients with Alzheimer's disease. , 1989, Clinical therapeutics.
[255] K. Yaffe,et al. Hormone replacement therapy to maintain cognitive function in women with dementia. , 2002, The Cochrane database of systematic reviews.
[256] Günther Deuschl,et al. Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.
[257] B. Steinhoff,et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. , 1999, Brain : a journal of neurology.
[258] P. Scheltens,et al. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. , 2000, European journal of neurology.
[259] D. Craig,et al. Galantamine for vascular cognitive impairment. , 2006, The Cochrane database of systematic reviews.
[260] T. Kurosaki,et al. Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.
[261] Dag Aarsland,et al. Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.
[262] T. del Ser,et al. Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia: A Randomized Placebo-Controlled Trial , 2005, Stroke.
[263] P Dal-Bianco,et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.
[264] K. Blennow,et al. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.
[265] O. Gefeller,et al. Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease , 1998, Annals of neurology.
[266] P. Whitehouse,et al. Mild cognitive impairment , 2006, Lancet.
[267] Bruno Dubois,et al. Testing cognition may contribute to the diagnosis of movement disorders , 1996, Neurology.
[268] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[269] J. Woo,et al. Age of Onset and Brain Atrophy in Alzheimer's Disease , 1997, International Psychogeriatrics.
[270] I G McKeith,et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies , 1999, Neurology.
[271] R J Harvey,et al. Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.
[272] H. Christensen,et al. Improving screening accuracy for dementia in a community sample by augmenting cognitive testing with informant report. , 2003, Journal of clinical epidemiology.
[273] B. Winblad,et al. Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.
[274] Charles DeCarli,et al. Radial width of the temporal horn: a sensitive measure in Alzheimer disease. , 2002, AJNR. American journal of neuroradiology.